Bovie Medical Corporation Announces Launch of Renuvion™: A New Brand Dedicated to the Cosmetic Surgery Market
March 29 2018 - 08:30AM
Business Wire
Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"),
a maker of medical devices and supplies and the developer of
J-Plasma®, a patented surgical product, today announced the launch
of Renuvion™, a new brand that is dedicated to the cosmetic surgery
market.
Bovie Medical’s J-Plasma technology will now be marketed and
sold in the cosmetic surgery market under the brand name, Renuvion.
The Renuvion brand will be marketed as a cosmetic technology and
will feature its own distinct logo, website and promotional
materials. The Company has also adopted two taglines related to the
Renuvion brand: Reshaping What’s Possible™ and What will you
renu?™
“On behalf of Bovie Medical, I am excited to announce the launch
of the Renuvion brand, which we have developed as part of our
commitment to enhancing our ability to commercialize our J-Plasma
technology in the cosmetic surgery market,” said Charlie Goodwin,
Chief Executive Officer. “The Renuvion brand – and its taglines:
Reshaping What’s Possible and What will you renu? – represent the
potential that we see for our transformational J-Plasma technology
to positively impact physician practices and the lives of their
patients. Most importantly, Renuvion was created specifically for
physicians in the cosmetic surgery market, including plastic
surgeons, cosmetic surgeons and dermatologists, who will be able to
leverage the increasing awareness of this brand as we establish
Bovie Medical as a provider of innovative technologies in this
market.”
Those interested in learning more are encouraged to visit:
https://www.Renuvion.com/
About Bovie Medical
Corporation:
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma®, a patented
plasma-based surgical product for cutting, coagulation and ablation
of soft tissue. J-Plasma® utilizes a helium ionization process to
produce a stable, focused beam of plasma that provides surgeons
with greater precision, and minimal invasiveness. The new
J-Plasma® handpieces with Cool-Coag™ technology deliver the
precision of helium plasma energy, the power of traditional
monopolar coagulation and the efficiency of plasma beam coagulation
- enabling thin-layer ablation and dissection and fast coagulation
with a single instrument, minimizing instrument exchange and
allowing a surgeon to focus on their patient and their
procedures. With Cool-Coag technology, the new J-Plasma
handpieces can deliver three distinctly different energy
modalities - further increasing the utility and versatility of the
J-Plasma system. Bovie Medical Corporation is also a leader in the
manufacture of a range of electrosurgical products and
technologies, marketed through both private labels and the
Company’s own well-respected brands (Bovie®, IDS™ and DERM™) to
distributors worldwide. The Company also leverages its expertise
through original equipment manufacturing (OEM) agreements with
other medical device manufacturers. For further information about
the Company’s current and new products, please refer to the
Investor Relations section of Bovie Medical Corporation
at www.boviemed.com.
Cautionary Statement on Forward-Looking
Statements:
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
Forward-looking information is subject to certain risks, trends
and uncertainties that could cause actual results to differ
materially from those projected. Many of these factors are beyond
the Company's ability to control or predict. Important factors that
may cause actual results to differ materially and that could impact
the Company and the statements contained in this release can be
found in the Company's filings with the Securities and Exchange
Commission including the Company's Report on Form 10-K for the year
ended December 31, 2016 and subsequent Form 10-Q filings. For
forward-looking statements in this release, the Company claims the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of
1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180329005109/en/
Investor Relations
Contact:Westwicke Partners on behalf of Bovie
Medical CorporationMike Piccinino,
CFA443-213-0500investor.relations@boviemed.com
Bovie (AMEX:BVX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bovie (AMEX:BVX)
Historical Stock Chart
From Mar 2023 to Mar 2024